TRIAL OF SIMVASTATIN TO SLOW THE PROGRESSION OF ALZHEIMER'S DISEASE

辛伐他汀减缓阿尔茨海默病进展的试验

• 批准号: 7375345
• 负责人: CANDICE J PERKINS
• 金额: $ 0.35万
• 依托单位: STATE UNIVERSITY NEW YORK STONY BROOK
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375345
• 关键词: TRIAL; SIMVASTATIN; SLOW; PROGRESSION; ALZHEIMER

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine the safety,tolerability and effectiveness of Simvastatin in lowering cholesterol levels and treating or slowing the progression of AD when compared to a placebo. Simvastatin is a Food and Drug Association approved drug used to lower cholesterol levels in the blood, treat heart conditions and reduce the risk of heart attack,stroke and death. The use of Simvastatin for Alzheimer's Disease is experimental. Ten to fifteen subjects from this facility are expected to participate in this study

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。本研究的目的是确定与安慰剂相比，辛伐他汀在降低胆固醇水平和治疗或减缓AD进展方面的安全性、耐受性和有效性。辛伐他汀是一种食品和药物协会批准的药物，用于降低血液中的胆固醇水平，治疗心脏病，降低心脏病发作，中风和死亡的风险。使用辛伐他汀治疗阿尔茨海默病是实验性的。预计该机构的10至15名受试者将参与本研究